<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE rss [<!ENTITY % HTMLlat1 PUBLIC "-//W3C//ENTITIES Latin 1 for XHTML//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml-lat1.ent">]>
<rss version="2.0" xml:base="http://www.novelix.com">
<channel>
 <title>Novelix Pharmaceuticals - Directed therapies for better cancer care. </title>
 <link>http://www.novelix.com</link>
 <description></description>
 <language>en</language>
<item>
 <title>Novelix Pharmaceuticals, Inc. Relocates to La Jolla, Expands Team</title>
 <link>http://www.novelix.com/news/attached</link>
 <description>&lt;p&gt;&lt;span style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-family: &#039;Times New Roman&#039;&quot;&gt;&lt;/p&gt;
&lt;div style=&quot;MARGIN: 0in 0in 0pt&quot; align=&quot;justify&quot;&gt;&lt;span&gt;&lt;strong&gt;La Jolla, CA, June 5, 2008&lt;/strong&gt; - Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first-in-class, small molecule cancer therapeutics, announced today that it successfully closed its Series A-3 Preferred Stock Financing allowing it to expand its team following its relocation from Pasadena, CA to La Jolla, CA.&lt;/span&gt;&lt;/div&gt;
&lt;p&gt;&lt;/span&gt;&lt;span style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-family: &#039;Times New Roman&#039;&quot;&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;img height=&quot;14&quot; alt=&quot;Download as a PDF file&quot; src=&quot;http://www.novelix.com/icons/pdf.gif&quot; width=&quot;14&quot; /&gt;&lt;/strong&gt;&amp;nbsp;&lt;a href=&quot;http://www.novelix.com/files/Novelix%20News%20Release%20Move%2020080605.pdf&quot;&gt;&lt;strong&gt;Download/view the full press release as a PDF file&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class=&quot;MsoNormal&quot; style=&quot;TEXT-JUSTIFY: inter-ideograph; MARGIN: 0pt; TEXT-ALIGN: justify&quot;&gt;&lt;span style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-family: &#039;Times New Roman&#039;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p class=&quot;MsoNormal&quot; style=&quot;TEXT-JUSTIFY: inter-ideograph; MARGIN: 0pt; TEXT-ALIGN: justify&quot; align=&quot;justify&quot;&gt;&lt;span style=&quot;FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-bidi-font-family: &#039;Times New Roman&#039;&quot;&gt;&lt;strong&gt;Pasadena, CA, February 26, 2007&lt;/strong&gt; - Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first in class small molecule cancer therapeutics, announced today that it has licensed its drug candidate NVX-207 to AOP Orphan Pharmaceuticals AG. The exclusive but restricted license will enable AOP Orphan Pharmaceuticals to develop and commercialize NVX-207 in human orphan designations in all territories outside the United States. Financial terms of the agreement were not disclosed.&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;&lt;img height=&quot;14&quot; alt=&quot;Download as a PDF file&quot; src=&quot;http://www.novelix.com/icons/pdf.gif&quot; width=&quot;14&quot; /&gt;&amp;nbsp;&lt;a href=&quot;http://www.novelix.com/files/Novelix%20-%20AOP%20News%20Release%2020070226.pdf&quot;&gt;&lt;font size=&quot;2&quot;&gt;Download/view the full press release as a PDF file&lt;/font&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt;
</description>
 <pubDate>Thu, 15 Dec 2005 17:36:54 -0800</pubDate>
</item>
</channel>
</rss>
